Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Imagem de Miniatura
Arquivos
art_DANILOVIC_Potential_role_of_sorafenib_as_neoadjuvant_therapy_in_2018.PDF (1.27 MB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2018
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
Autores
Citação
ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.62, n.3, p.370-375, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/28312
Referências
  1. Ark N, 2008, SURG ONCOL CLIN N AM, V17, P145, DOI 10.1016/j.soc.2007.10.009
  2. Barbier L, 2011, INT J HEPATOL, DOI 10.4061/2011/791013
  3. Besic N, 2013, THYROID, V23, P178, DOI 10.1089/thy.2012.0194
  4. Besic N, 2012, THYROID, V22, P131, DOI 10.1089/thy.2011.0243
  5. Borregales LD, 2016, THER ADV UROL, V8, P130, DOI 10.1177/1756287215612962
  6. Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8
  7. Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
  8. Cleary JM, 2010, J CLIN ONCOL, V28, pE390, DOI 10.1200/JCO.2009.27.4225
  9. Cowey CL, 2010, J CLIN ONCOL, V28, P1502, DOI 10.1200/JCO.2009.24.7759
  10. Dang RP, 2016, INT J SURG ONCOL, V2016
  11. Hoftijzer H, 2009, EUR J ENDOCRINOL, V161, P923, DOI 10.1530/EJE-09-0702
  12. Ito Y, 2012, ENDOCR J, V59, P839, DOI 10.1507/endocrj.EJ12-0174
  13. Kiess AP, 2016, HEAD NECK-J SCI SPEC, V38, P493, DOI 10.1002/hed.24357
  14. Loibl S, 2014, BREAST CARE, V9, P169, DOI 10.1159/000363430
  15. Nixon IJ, 2016, THYROID, V26, P373, DOI 10.1089/thy.2015.0315
  16. Orosco RK, 2015, THYROID, V25, P125, DOI 10.1089/thy.2014.0116
  17. Schlumberger M, 2014, J CLIN ONCOL, V32
  18. Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
  19. Shah DR, 2014, DRUG SAFETY, V37, P135, DOI 10.1007/s40264-014-0139-x
  20. Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102
  21. Wada N, 2007, J CLIN ENDOCR METAB, V92, P215, DOI 10.1210/jc.2006-1443

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - LIM/43
Carregar mais